Literature DB >> 25690523

Oculocutaneous albinism in a patient with 17p13.2-pter duplication - a review on the molecular syndromology of 17p13 duplication.

Marzena Kucharczyk1, Aleksandra Jezela-Stanek1, Dorota Gieruszczak-Bialek1,2, Monika Kugaudo1,3, Agata Cieslikowska1, Magdalena Pelc1, Malgorzata Krajewska-Walasek1.   

Abstract

BACKGROUND: Chromosomal duplications involving 17p13.3 have recently been defined as a new distinctive syndrome with several diagnosed patients. Some variation is known to occur in the breakpoints of the duplicated region and, consequently, in the phenotype as well. AIMS: We report on a patient, the fifth to our knowledge, a 4-year-old girl with a pure de novo subtelomeric 17p13.2-pter duplication. She presents all of the facial features described so far for this duplication and in addition, a unilateral palmar transversal crease and oculocutaneous albinism which has not been reported previously.
METHODS: A detailed molecular description of the reported aberration and correlation with the observed phenotypical features based on a literature review. We discuss the possible molecular etiology of albinism in regard to the mode of inheritance.
CONCLUSION: The new data provided here may be useful for further genotype correlations in syndromes with oculocutaneous albinism, especially of autosomal dominant inheritance.

Entities:  

Keywords:  17p13.3; albinism; chromosomal duplication

Mesh:

Year:  2015        PMID: 25690523     DOI: 10.5507/bp.2015.003

Source DB:  PubMed          Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub        ISSN: 1213-8118            Impact factor:   1.245


  1 in total

1.  Neuronal migration genes and a familial translocation t (3;17): candidate genes implicated in the phenotype.

Authors:  Meriam Hadj Amor; Sarra Dimassi; Amel Taj; Wafa Slimani; Hanene Hannachi; Adnene Mlika; Khaled Ben Helel; Ali Saad; Soumaya Mougou-Zerelli
Journal:  BMC Med Genet       Date:  2020-02-06       Impact factor: 2.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.